Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to -$3.2 million.

  • Lipocine's Net Income towards Common Stockholders fell 3521.29% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.5 million, marking a year-over-year decrease of 3149.84%. This contributed to the annual value of -$8814.0 for FY2024, which is 9994.68% up from last year.
  • Lipocine's Net Income towards Common Stockholders amounted to -$3.2 million in Q3 2025, which was down 3521.29% from -$2.2 million recorded in Q2 2025.
  • In the past 5 years, Lipocine's Net Income towards Common Stockholders registered a high of $12.6 million during Q4 2021, and its lowest value of -$6.8 million during Q2 2021.
  • Its 5-year average for Net Income towards Common Stockholders is -$1.9 million, with a median of -$2.7 million in 2022.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first surged by 37983.26% in 2021, then tumbled by 15247.7% in 2025.
  • Over the past 5 years, Lipocine's Net Income towards Common Stockholders (Quarter) stood at $12.6 million in 2021, then tumbled by 117.94% to -$2.3 million in 2022, then decreased by 1.35% to -$2.3 million in 2023, then soared by 177.51% to $1.8 million in 2024, then crashed by 279.18% to -$3.2 million in 2025.
  • Its last three reported values are -$3.2 million in Q3 2025, -$2.2 million for Q2 2025, and -$1.9 million during Q1 2025.